# A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

> **NCT01561963** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 21 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Rifampin Oral Capsules
- **DRUG:** Rifampin IV Solution

## Key facts

- **NCT ID:** NCT01561963
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-01
- **Primary completion:** 2012-04-01
- **Final completion:** 2012-04-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561963, "A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01561963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*